Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213085 | 0.82 | ALDH1A1 (0.48) | PIK3CA | |
| SCHEMBL14213086 | 0.79 | MAP4K1 (0.34) | PARP1MCHR1 | |
| SCHEMBL25759811 | 0.78 | NOS3 (0.36) | PARP1 | |
| SCHEMBL14182600 | 0.77 | KCNH2 (0.34) | KCNH2CD274PARP1DYRK1ASLC2A1 | |
| SCHEMBL14213087 | 0.75 | ALDH1A1 (0.41) | KCNH2CD274PARP1 | |
| SCHEMBL14213088 | 0.71 | DPP7 (0.48) | PARP1 | |
| SCHEMBL14213161 | 0.71 | KDM4E (0.38) | — | |
| SCHEMBL14213771 | 0.70 | KDM4E (0.39) | — | |
| SCHEMBL14213343 | 0.70 | S1PR2 (0.43) | — | |
| SCHEMBL26788485 | 0.69 | NOS3 (0.33) | ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | KCNH2 1230/4885CD274 2418/4885PARP1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.